复星医药：枸橼酸伏维西利胶囊新增适应症药品注册申请获批

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a new indication for the drug FCN-437c (commercial name: Fuzhuoning), which is a CDK4/6 inhibitor for treating HR-positive, HER2-negative locally advanced or metastatic breast cancer in adults [1] Group 1 - The newly approved indication is for use in combination with aromatase inhibitors as initial endocrine therapy [1] - The drug is an innovative small molecule with independent intellectual property rights owned by the group [1] - FCN-437c was included in the national "Major New Drug Creation" science and technology major project in 2018 [1]